<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02776813</url>
  </required_header>
  <id_info>
    <org_study_id>UT-201501</org_study_id>
    <secondary_id>ATTCK-20-2</secondary_id>
    <nct_id>NCT02776813</nct_id>
  </id_info>
  <brief_title>Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma</brief_title>
  <official_title>Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Unum Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Unum Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and
      efficacy of an autologous T-cell product expressing ACTR in combination with rituximab in
      subjects with refractory or relapsed CD20+ B-cell lymphoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">February 12, 2020</completion_date>
  <primary_completion_date type="Actual">February 12, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as assessed by dose limiting toxicities (DLTs)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by determination of the maximum tolerated dose (MTD)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by determination of the recommended phase 2 dose (RP2D)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by and adverse events, laboratory assessments and physical examinations</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as assessed by mini-mental state examination (MMSE)</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>60 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>ACRT087 persistence</measure>
    <time_frame>60 months</time_frame>
    <description>Blood samples will be collected and analyzed for the presence of T-cells which express antibody coupled T-cell receptors, using flow cytometry and qPCR</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum inflammatory markers</measure>
    <time_frame>169 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Serum cytokine levels</measure>
    <time_frame>169 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Rituximab serum concentrations</measure>
    <time_frame>147 days</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>ACTR087, in combination with rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACTR087</intervention_name>
    <arm_group_label>ACTR087, in combination with rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <arm_group_label>ACTR087, in combination with rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent obtained prior to study procedures

          -  Histologically-confirmed relapsed or refractory CD20+ B-cell lymphoma of one of the
             following types, with documented disease progression or recurrence following the
             immediate prior therapy:

               -  DLBCL, regardless of cell of origin or underlying molecular genetics

               -  MCL

               -  PMBCL

               -  Gr3b-FL

               -  TH-FL

          -  Biopsy-confirmed CD20+ expression of the underlying malignancy by immunohistochemical
             staining or flow cytometry between the most recent dose of an anti-CD20 monoclonal
             antibody (mAb) and study enrollment

          -  At least 1 measurable lesion on imaging. Lesions that have been previously irradiated
             will be considered measurable only if progression has been documented following
             completion of radiation therapy

          -  Must have received adequate prior therapy for the underlying CD20+ B-cell lymphoma,
             defined as an anti-CD20 mAb in combination with an anthracycline-containing
             chemotherapy regimen (i.e. chemo-immunotherapy) and at least one of the following:

               -  biopsy-proven refractory disease after frontline chemo-immunotherapy

               -  relapse within 1 year from frontline chemo-immunotherapy and ineligible for
                  autologous hematopoietic stem cell transplant (auto-HSCT)

               -  For subjects with DLBCL, PMBCL, and Gr3b-FL: relapsed or refractory disease
                  following at least 2 prior regimens or following an auto-HSCT

               -  For subjects with TH-FL: relapsed or refractory disease following at least 2
                  prior regimens or following an auto-HSCT. At least 1 prior regimen with an
                  anti-CD20 mAb in combination with chemotherapy is required following documented
                  transformation

               -  For subjects with MCL (confirmed with cyclin D1 expression or evidence of
                  t(11;14) by cytogenetics, fluorescent in situ hybridization (FISH) or PCR):
                  relapsed or refractory disease after at least 1 prior regimen with
                  chemo-immunotherapy (prior auto-HSCT is allowable)

          -  Karnofsky performance scale ≥ 60%

          -  Life expectancy of at least 6 months

          -  ANC &gt; 1000/µL

          -  Platelet count &gt; 50,000/µL

          -  For women of childbearing potential (defined as physiologically capable of becoming
             pregnant), agreement to use of highly effective contraception for at least 1 year
             following ACTR087 infusion. For men with partners of childbearing potential, agreement
             to use effective barrier contraception for at least 1 year following ACTR087 infusion

        Exclusion Criteria:

          -  Known active central nervous system (CNS) involvement by malignancy. Subjects with
             prior CNS involvement with their lymphoma must have completed effective treatment of
             their CNS disease at least 3 months prior to enrollment with no evidence of disease
             clinically and at least stable findings on relevant CNS imaging

          -  Prior treatment as follows:

               -  alemtuzumab within 6 months of enrollment

               -  fludarabine, cladribine, or clofarabine within 3 months of enrollment

               -  external beam radiation within 2 weeks of enrollment

               -  mAb (including rituximab) within 2 weeks of enrollment

               -  other lymphotoxic chemotherapy (including steroids except as below) within 2
                  weeks of enrollment

               -  experimental agents within 3 half-lives prior to enrollment, unless progression
                  is documented on therapy

          -  Serum creatinine ≥ 1.5 X age-adjusted upper limits of normal (ULN)

          -  Pulse oximetry &lt; 92% on room air

          -  Direct bilirubin ≥ 3.0 mg/dL (50 mmol/L)

          -  Alanine transaminase (ALT) ≥ 3 times the ULN, unless determined to be directly due to
             lymphoma.

          -  Aspartate transaminase (AST) ≥ 3 times the ULN, unless determined to be directly due
             to lymphoma

          -  Class III or IV heart failure as defined by the New York Heart Association (NYHA),
             history of cardiac angioplasty or stenting, documented myocardial infarction or
             unstable angina within 6 months prior to enrollment, cardiac ejection fraction of &lt;
             45%, or other clinically significant cardiac disease

          -  Clinical history of, prior diagnosis of, or overt evidence of autoimmune disease,
             regardless of severity

          -  Clinically significant active infection, in the judgment of the investigator

          -  Pregnancy (negative serum pregnancy test to be obtained within 6 days prior to
             enrollment for subjects of childbearing potential)

          -  Breastfeeding

          -  Primary immunodeficiency

          -  Seropositive for Human Immunodeficiency Virus (HIV) 1 or HIV 2, or positive hepatitis
             B surface antigen (HBsAg) or hepatitis C antibody

          -  Will need or has needed active treatment of a second malignancy within the prior 3
             years before enrollment, other than FL, non-melanoma skin cancers, localized prostate
             cancer treated with curative intent, or cervical carcinoma in situ

          -  Is unable to receive any of the agents used in this study due a history of severe
             immediate hypersensitivity reaction (e.g. hypersensitivity to dimethyl sulfoxide
             (DMSO))

          -  History of prior allogeneic HSCT

          -  History of Richter's transformation from CLL

          -  Prior infusion of a genetically modified therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Sachs, MD</last_name>
    <role>Study Director</role>
    <affiliation>Unum Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loyola University Chicago</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Bone and Marrow Transplantation</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 4, 2016</study_first_submitted>
  <study_first_submitted_qc>May 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2016</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD20+</keyword>
  <keyword>B-cell</keyword>
  <keyword>ACTR087</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

